SEC Tracker
Get the app
IGC · XBRL financial data

IGC Pharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (IGC's year ends in late December)

In thousands of dollarsMar 31, 2021Mar 31, 2022Mar 31, 2023Mar 31, 2024Mar 31, 2025Dec 31, 2025
Revenue8983979111,3451,271—
Cost of revenue785203469612652—
Gross profit113194442733619—
Research and development9292,3303,4613,7733,655—
Selling, general and administrative7,90813,2928,5526,7584,410—
Operating income (loss)(8,724)(15,428)(11,571)(9,798)(7,446)—
Interest expense35555—
Other income (expense)8246165143325—
Income tax expense (benefit)00000—
Net income (loss)(8,811)(15,016)(11,506)(13,000)(7,122)—
Earnings per share, basic USD per share———(0.22)(0.09)—
Earnings per share, diluted USD per share———(0.22)(0.09)—
Weighted average shares, basic thousands of shares41,96349,99252,57658,84076,517—
Weighted average shares, diluted thousands of shares———58,84076,517—

Balance sheet

CSV

Fiscal years (IGC's year ends in late December)

In thousands of dollarsMar 31, 2021Mar 31, 2022Mar 31, 2023Mar 31, 2024Mar 31, 2025Dec 31, 2025
Cash and cash equivalents14,54810,4603,1961,198405900
Short-term investments8001540038
Marketable securities00154———
Accounts receivable175125107393412
Inventory5,4783,5482,6511,5401,360640
Prepaid and other current assets3,236978358208395200
Total current assets23,51715,1116,4663,7052,8961,790
Property and equipment, net10,8409,4198,2133,6953,2202,141
Right-of-use asset4884503261989811
Total assets35,86726,83417,1789,9028,7479,712
Accounts payable4769815307738831,014
Accrued liabilities1,5881,4571,3681,5671,3741,142
Total current liabilities2,3682,4411,8982,3402,2572,156
Long-term debt276144141137134131
Lease liability, non-current40534120784102
Total liabilities3,0642,9422,2672,5812,4172,289
Accumulated deficit(74,143)(89,159)(100,665)(113,665)(120,744)(124,890)
Total stockholders' equity32,80323,89214,9117,3216,3307,423
Total liabilities and equity35,86726,83417,1789,9028,7479,712
Common shares outstanding (cover page) thousands of shares48,32751,74453,07775,63683,89298,796

Cash flows

CSV

Fiscal years (IGC's year ends in late December)

In thousands of dollarsMar 31, 2021Mar 31, 2022Mar 31, 2023Mar 31, 2024Mar 31, 2025Dec 31, 2025
Net income (loss)(8,811)(15,016)(11,506)(13,000)(7,122)—
Stock-based compensation7037,0005,5004,6004,300—
Depreciation and amortization478651657637618—
Net cash from operating activities(10,800)(7,462)(7,047)(5,199)(4,795)—
Purchases of property and equipment1,470207310138112—
Net cash from investing activities3,387(742)(235)(317)(442)—
Proceeds from issuing common stock14,158—1033,0274,454—
Proceeds from issuing equity04,145103———
Repayments of long-term debt————3—
Net cash from financing activities14,6884,1421003,5244,451—
Net change in cash7,290(4,088)(7,264)(1,998)(793)—

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
IGC Pharma331265(1,350)*103.4M0.3 quarters 10-QJun 30, 2026
Cognition Therapeutics34,012not reported(3,053)*95.1M11.1 quarters 10-QJun 30, 2026
Relmada Therapeutics11,334not reported(9,606)*106.7M22.7 quarters 10-QJun 30, 2026
CEL-SCI6,527not reported(4,031)*17.6M1.6 quarters 10-QJun 30, 2026
Charlie's Holdings527not reported(383)*280.6M1.4 quarters 10-QJun 30, 2026
Ernexa Therapeutics5,028not reported(4,152)*1.6M1.2 quarters 10-QJun 30, 2026
Marker Therapeutics11,331not reported(3,716)*16.7M3.0 quarters 10-QJun 30, 2026
Lipocine4,979190(3,028)*8.2M7.7 quarters 10-QJun 30, 2026
Fibrogen50,644(1,474)(3,991)*4.0M22.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.